Category Archives: Business and Investments

Latest From Business and Investments

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Emerging Company Policy Deconstructed: Fostering Innovation Act (H.R. 2629)

scientists115x76

In a nutshell: Representative Michael Fitzpatrick (R-PA) introduced H.R. 2629, the Fostering Innovation Act, to update SEC filing status classifications for public companies and help ease regulatory burdens on emerging companies and reduce the bureaucratic hurdles and red tape that lengthen the time to bring cures from discovery to patient. Why you should care: SEC Rule 12b-2 establishes three classifications for public companies to determine their filing status, which include large accelerated filers (companies with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

The Value of Partnering Continues to be a Draw for BIO Events

Last month’s BIO Convention in China saw 700 partnering meetings between executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia. These meetings allowed industry executives to meet and explore business opportunities with China’s emerging biotech sector. One company in particular, SciClone Pharmaceuticals, invited BioWorld to tag along for the day and get an insider’s look at what a full day of partnering entails. To better understand the full scope of participating in these partnering meetings, read Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Stocks Hit Record Highs…Again

BIOtech-stocks

Biotech stocks hit an all-time high this week, driven by strong performance among large cap sector leaders with strong product portfolios. A common benchmark for the sector, the NASDAQ Biotechnology Index (NBI) has outperformed the S&P 500 by a factor of over 2X. The NBI is up 61% year to date, compared with 26% for the S&P 500. We’ll be discussing this strong performance in New York this February at the BIO CEO & Investor Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

NYC Launches $100M Life Science Fund

On Tuesday, Deputy Mayor Robert Steel announced that the city is launching the New York City Emerging Life Science Technology Investment Fund, a $100 million venture fund for life sciences research. New York City will invest $10 million along with $40 million from Eli Lilly, Celgene and GE Ventures, with the remaining $50 million matched by venture capital partnerships. The fund will be used to invest in 15-20 early-stage research and development companies by 2020. Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,